BioCryst Pharmaceuticals | BCRX - Capital Social Ordinario





Capital Social Ordinario Cambio Fecha
Alnylam Pharmaceuticals USD 133.73M 290K 2026-06
BioCryst Pharmaceuticals USD 255.26M 42.2M 2026-06
Chugai Pharma JPY 1.65B 460K 2026-06
Daiichi Sankyo JPY 1.82B 30.68M 2026-06
DBV Technologies USD 235.6M 98.78M 2025-12
Enanta Pharmaceuticals USD 212K 1000 2023-12
Gilead Sciences USD 1.24B 1000K 2026-06
GlaxoSmithKline GBP 4.08B 20.6M 2026-06
Glaxosmithkline GBP 4.05B 20.6M 2026-03
Incyte USD 200.98M 1.03M 2026-06
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
Karyopharm Therapeutics USD 22.54M 4.23M 2026-03
Neurocrine Biosciences USD 100.55M 50K 2026-06
Novavax USD 162.58M 106K 2025-12
PTC Therapeutics USD 82.88M 1.41M 2026-03
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Roche Holding CHF 796.77M 1.15M 2026-06
Sarepta Therapeutics USD 105.62M 53K 2026-06
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vertex Pharmaceuticals USD 253.3M 900K 2026-06